Senti Biosciences Holdings, Inc. has dismissed KPMG LLP as its independent registered public accounting firm, effective November 17, 2026. The decision was approved by the company's Audit Committee. The company has since engaged KNAV CPA LLP as its new auditor, with the Audit Committee approving this engagement on November 20, 2026.

The filing details the status of the company's financial reporting relationship with KPMG. The firm's audit reports for the fiscal years ended December 31, 2025 and 2024 did not contain an adverse opinion or a disclaimer of opinion. However, both reports included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern. This doubt was attributed to the company's recurring losses, negative cash flows from operations, and accumulated deficit.

The filing also confirms that there were no disagreements between the company and KPMG regarding accounting principles, financial statement disclosure, or auditing scope. The only exception noted was a material weakness in the company's internal control over financial reporting that existed as of December 31, 2024. This weakness stemmed from a lack of sufficient resources in the finance and accounting function, which resulted in ineffective process level control activities over non-routine transactions. Management concluded that this material weakness was remediated during the fiscal year ended December 31, 2025.

KPMG has been authorized to respond fully to inquiries from KNAV regarding the material weakness. A copy of KPMG's letter agreeing with the statements made in the filing has been included as Exhibit 16.1.